Literature DB >> 23957947

Current perspectives in the use of molecular imaging to target surgical treatments for genitourinary cancers.

Francesco Greco1, Jeffrey A Cadeddu2, Inderbir S Gill3, Jihad H Kaouk4, Mesut Remzi5, R Houston Thompson6, Fijs W B van Leeuwen7, Henk G van der Poel8, Paolo Fornara9, Jens Rassweiler10.   

Abstract

CONTEXT: Molecular imaging (MI) entails the visualisation, characterisation, and measurement of biologic processes at the molecular and cellular levels in humans and other living systems. Translating this technology to interventions in real-time enables interventional MI/image-guided surgery, for example, by providing better detection of tumours and their dimensions.
OBJECTIVE: To summarise and critically analyse the available evidence on image-guided surgery for genitourinary (GU) oncologic diseases. EVIDENCE ACQUISITION: A comprehensive literature review was performed using PubMed and the Thomson Reuters Web of Science. In the free-text protocol, the following terms were applied: molecular imaging, genitourinary oncologic surgery, surgical navigation, image-guided surgery, and augmented reality. Review articles, editorials, commentaries, and letters to the editor were included if deemed to contain relevant information. We selected 79 articles according to the search strategy based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis criteria and the IDEAL method. EVIDENCE SYNTHESIS: MI techniques included optical imaging and fluorescent techniques, the augmented reality (AR) navigation system, magnetic resonance imaging spectroscopy, positron emission tomography, and single-photon emission computed tomography. Experimental studies on the AR navigation system were restricted to the detection and therapy of adrenal and renal malignancies and in the relatively infrequent cases of prostate cancer, whereas fluorescence techniques and optical imaging presented a wide application of intraoperative GU oncologic surgery. In most cases, image-guided surgery was shown to improve the surgical resectability of tumours.
CONCLUSIONS: Based on the evidence to date, image-guided surgery has promise in the near future for multiple GU malignancies. Further optimisation of targeted imaging agents, along with the integration of imaging modalities, is necessary to further enhance intraoperative GU oncologic surgery.
Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Augmented reality; Genitourinary oncologic surgery; Image-guided surgery; Molecular imaging; Surgical navigation

Mesh:

Year:  2013        PMID: 23957947     DOI: 10.1016/j.eururo.2013.07.033

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  10 in total

1.  Organ-sparing procedures in GU cancer: part 1-organ-sparing procedures in renal and adrenal tumors: a systematic review.

Authors:  Raouf Seyam; Mahmoud I Khalil; Mohamed H Kamel; Waleed M Altaweel; Rodney Davis; Nabil K Bissada
Journal:  Int Urol Nephrol       Date:  2019-01-08       Impact factor: 2.370

2.  Augmented Bladder Tumor Detection Using Deep Learning.

Authors:  Eugene Shkolyar; Xiao Jia; Timothy C Chang; Dharati Trivedi; Kathleen E Mach; Max Q-H Meng; Lei Xing; Joseph C Liao
Journal:  Eur Urol       Date:  2019-09-17       Impact factor: 20.096

3.  Optimization of sentinel lymph node mapping in bladder cancer using near-infrared fluorescence imaging.

Authors:  B E Schaafsma; F P R Verbeek; H W Elzevier; Q R J G Tummers; J R van der Vorst; J V Frangioni; C J H van de Velde; R C M Pelger; A L Vahrmeijer
Journal:  J Surg Oncol       Date:  2014-08-11       Impact factor: 3.454

4.  Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease.

Authors:  William P Parker; Brian J Davis; Sean S Park; Kenneth R Olivier; Richard Choo; Mark A Nathan; Val J Lowe; Timothy J Welch; Jaden D Evans; William S Harmsen; Harras B Zaid; Ilya Sobol; Daniel M Moreira; Rimki Haloi; Matthew K Tollefson; Matthew T Gettman; Stephen A Boorjian; Lance A Mynderse; R Jeffrey Karnes; Eugene D Kwon
Journal:  Eur Urol       Date:  2016-09-03       Impact factor: 20.096

5.  Patterns of Recurrence After Postprostatectomy Fossa Radiation Therapy Identified by C-11 Choline Positron Emission Tomography/Computed Tomography.

Authors:  William P Parker; Jaden D Evans; Bradley J Stish; Sean S Park; Kenneth Olivier; Richard Choo; Mark A Nathan; Brian T Welch; R Jeffrey Karnes; Lance A Mynderse; Thomas M Pisansky; Eugene D Kwon; Val J Lowe; Brian J Davis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-17       Impact factor: 7.038

Review 6.  Advances in imaging technologies in the evaluation of high-grade bladder cancer.

Authors:  Dimitar V Zlatev; Emanuela Altobelli; Joseph C Liao
Journal:  Urol Clin North Am       Date:  2015-02-28       Impact factor: 2.241

7.  Urovision 2020: The future of urology.

Authors:  Vivek Venkatramani
Journal:  Indian J Urol       Date:  2015 Apr-Jun

Review 8.  Image-Guided Transurethral Resection of Bladder Tumors - Current Practice and Future Outlooks.

Authors:  Timothy C Chang; Gautier Marcq; Bernhard Kiss; Dharati R Trivedi; Kathleen E Mach; Joseph C Liao
Journal:  Bladder Cancer       Date:  2017-07-27

9.  Intraoperative assessment and postsurgical treatment of prostate cancer tumors using tumor-targeted nanoprobes.

Authors:  James Teh; Manisha Tripathi; Derek Reichel; Bien Sagong; Ricardo Montoya; Yi Zhang; Shawn Wagner; Rola Saouaf; Leland W K Chung; J Manuel Perez
Journal:  Nanotheranostics       Date:  2021-01-01

10.  Multimodal hybrid imaging agents for sentinel node mapping as a means to (re)connect nuclear medicine to advances made in robot-assisted surgery.

Authors:  Gijs H KleinJan; Nynke S van den Berg; Jeroen de Jong; Esther M Wit; Helene Thygessen; Erik Vegt; Henk G van der Poel; Fijs W B van Leeuwen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-15       Impact factor: 9.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.